In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 3 Expert Committee has revised the Metformin Hydrochloride Extended-Release Tablets monograph. The purpose of this revision is to add *Dissolution Test 22* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s).

A typographical error was noted in the original Notice of Intent to Revise; the corrected text is included.

The Metformin Hydrochloride Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Robyn Fales, Scientist IV (240-221-2047 or rmp@usp.org).